Nherera, L., Marks, D., Minhas, Rubin, Thorogood, Margaret and Humphries, Steve E.. (2011) Probabilistic cost-effectiveness analysis of cascade screening for familial hypercholesterolaemia using alternative diagnostic and identification strategies. Heart, Vol.97 (No.1175). e1181. ISSN 1355-6037

Preview

PDF WRAP_Thorogood_Nherera_at_al_Revised_final_230311.pdf - Accepted Version - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader Download (757Kb)

Abstract

Objective To estimate the probabilistic cost-effectiveness of cascade screening methods in familial hypercholesterolaemia (FH) from the UK NHS perspective. Design Economic evaluation (cost utility analysis) comparing four cascade screening strategies for FH: Using low-density lipoprotein (LDL) cholesterol measurements to diagnose affected relatives (cholesterol method); cascading only in patients with a causative mutation identified and using DNA tests to diagnose relatives (DNA method); DNA testing combined with LDL-cholesterol testing in families with no mutation identified, only in patients with clinically defined ‘definite’ FH (DNA+DFH method); DNA testing combined with LDL-cholesterol testing in no-mutation families of both ‘definite’ and ‘probable’ FH patients (DNA+DFH+PFH). A probabilistic model was constructed to estimate the treatment benefit from statins, with all diagnosed individuals receiving high-intensity statin treatment. Population A cohort of 1000 people suspected of having FH aged 50 years for index cases and 30 years for relatives, followed for a lifetime. Main outcomes Costs, quality-adjusted life-years (QALY) and incremental cost-effectiveness ratios (ICER). Results The DNA+DFH+PFH method was the most cost-effective cascade screening strategy. The ICER was estimated at £3666/QALY. Using this strategy, of the tested relatives 30.6% will be true positives, 6.3% false positives, 61.9% true negatives and 1.1% false negatives. Probabilistic sensitivity analysis showed that this approach is 100% cost-effective using the conventional benchmark for cost-effective treatments in the NHS of between £20 000 and £30 000 per QALY gained. Conclusion Cascade testing of relatives of patients with DFH and PFH is cost-effective when using a combination of DNA testing for known family mutations and LDL-cholesterol levels in the remaining families. The approach is more cost-effective than current primary prevention screening strategies.

[error in script] [error in script]

Item Type:	Journal Article
Subjects:	R Medicine > RA Public aspects of medicine
Divisions:	Faculty of Medicine > Warwick Medical School
Library of Congress Subject Headings (LCSH):	Medical screening -- Cost effectiveness, Hypercholesteremia -- Diagnosis -- Cost effectiveness, Hypercholesteremia -- Diagnosis -- Evaluation
Journal or Publication Title:	Heart
Publisher:	B M J Group
ISSN:	1355-6037
Date:	2011
Volume:	Vol.97
Number:	No.1175
Page Range:	e1181
Identification Number:	10.1136/hrt.2010.213975
Status:	Peer Reviewed
Publication Status:	Published
Access rights to Published version:	Restricted or Subscription Access
Funder:	National Collaborating Centre for Primary Care (Great Britain) (NCCPC), National Institute for Health and Clinical Excellence (Great Britain) (NICE)
References:	References 1. Austin MA, Hutter CM, Zimmern RL et al. Genetic causes of monogenic heterozygous familial hypercholesterolemia: a HuGE prevalence review. Am J Epidemiol 2004; 160:407-420. 2. Marks D, Thorogood M, Neil HA et al. A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia. Atherosclerosis 2003;168:1-14. 3. Varret M, Abifadel M, Rabes JP, Boileau C: Genetic heterogeneity of autosomal dominant hypercholesterolemia. Clin Genet 2008; 73:1-13. 4. Betteridge D. Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management. Athereosclerosis 1999; 142:105-112. 5. Neil A, Cooper J, Betteridge J et al. Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study. Eur Heart J 2008; 29:2625-33. 6. Marks D, Thorogood M, Farrer JM, Humphries SE. Census of clinics providing specialist lipid services in the United Kingdom. J Public Health 2004; 26:353-354. 7. The Simon Broome Register Group. Scientific Steering Committee on behalf of The Simon Broome Register Group. The risk of fatal coronary heart disease in familial hypercholesterolaemia. BMJ 1991; 303:893-896. 8. Kwiterovich PO Jrn, Fredrickson DS, Levy RI. Familial hypercholesterolemia (one form of familial type II hyperlipoproteinemia). A study of its biochemical, genetic and clinical presentation in childhood. Journal of Clinical Invest 1974; 53:1237-1249. 9. Leonard JV, Whitelaw AG, Wolff OH et al. Diagnosing familial hypercholesterolaemia in childhood by measuring serum cholesterol. Br Med J. 1977; 18; 1:1566-8. 10. Starr B, Hadfield SG, Hutten BA, et al. Development of sensitive and specific age- and gender-specific low-density lipoprotein cholesterol cut-offs for diagnosis of first-degree relatives with familial hypercholesterolaemia in cascade testing. Clin Chem and Lab 2008; 46:791-803. 11. Graham CA, McIlhatton BP, Kirk CW et al. Genetic screening protocol for familial hypercholesterolemia which includes splicing defects gives an improved mutation detection rate. Atherosclerosis 2005; 182:331-340. 12. Humphries SE, Whittall RA, Hubbart CS et al. Genetic causes of familial hypercholesterolaemia in patients in the UK: relation to plasma lipid levels and coronary heart disease risk. J Med Genet 2006; 43:943-949. 13. Taylor A, Wang D, Patel et al. Mutation detection rate and spectrum in familial hypercholesterolaemia patients in the UK pilot cascade project. Clin Genet 2010; 77:572-580. 14. DeMott K, Nherera L, Shaw EJ et al. Clinical Guidelines and Evidence Review for Familial hypercholesterolaemia: the identification and management of adults and children with familial hypercholesterolaemia. 2008. London: National Collaborating Centre for Primary Care and Royal College of General Practitioners. 15. Minhas R, Humphries SE, Qureshi N, Neil HA; NICE Guideline Development Group. Controversies in familial hypercholesterolaemia: recommendations of the NICE Guideline Development Group for the identification and management of familial hypercholesterolaemia. Heart. 2009 Apr;95(7):584-7 16. Hadfield SG, Horara S, Starr BJ et al. Steering Group for the Department of Health Familial Hypercholesterolaemia Cascade Testing Audit Project. Family tracing to identify patients with familial hypercholesterolaemia: the second audit of the Department of Health Familial Hypercholesterolaemia Cascade Testing Project. Ann Clin Biochem.2009; 46:24-32. 17. Health Survey of England 2003 http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsStatistics/DH_4098712 18. Nherera L, Calvert NW, DeMott K et al. Cost-effectiveness analysis of the use of a high-intensity statin compared to a low-intensity statin in the management of patients with familial hypercholesterolaemia. Curr Med Res Opin 2010; 26:529–36. 19. Hadfield SG, Horara S, Starr BJ et al. Steering Group for the Department of Health Familial Hypercholesterolaemia Cascade Testing Audit Project. Family tracing to identify patients with familial hypercholesterolaemia: the second audit of the Department of Health Familial Hypercholesterolaemia Cascade Testing Project. Ann Clin Biochem.2009; 46:24-32. 20. Government Actuary's Department. Interim Life Tables: Governement Actuary's Department, 2006 http://www.gad.gov.uk/Demography_Data/Life_Tables/Interim_life_tables.asp 21. National Institute for Health and Clinical Excellence. Statins for the prevention of cardiovascular events. Technology Appraisal http://www.nice.org.uk/Guidance/TA94. London: National Institute for Health and Clinical Excellence, 2006. 22. Huxley RR, Hawkins MH, Humphries SE et al. Simon Broome Familial Hyperlipidaemia Register Group and Scientific Steering Committee. Risk of fatal stroke in patients with treated familial hypercholesterolemia: a prospective registry study. Stroke. 2003; 34:22-5. 23. LaRosa JC, Grundy SM, Waters DD et al. Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease. N Eng J Med 2005;352:1425-1435. 24. Pedersen TR, Faergeman O, Kastelein JJP et al. High-dose atorvastatin vs usual-sose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 2005;294:2437-2445. 25. Cannon CP, Braunwald E, McCabe CH et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-504. 26. de Lemos JA, Blazing MA, Wiviott SD et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes phase Z of the A to Z Trial. JAMA 2004;292:1307-16. 27. British National Formulary March 2011 Number 61. Available from http://bnf.org/bnf/index.htm 28. Curtis, L. & Netten, A. (2010) Unit Costs of Health and Social Care 2010, Personal Social Services Research 29. Department of Health, NHS reference costs 2010/11. Reference Costs 2010. Available http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_111591 30. Health survey of England 1996, Adjusting utility for age http://www.archive.official-documents.co.uk/document/doh/survey96/tab5-29.htm 31. Taylor F, Ward K, Moore THM, Burke M, Davey Smith G, Casas JP, Ebrahim S. Statins for the primary prevention of cardiovascular disease. Cochrane Database of Systematic Reviews 2011, Issue 1. Art. No.: CD004816. DOI: 10.1002/14651858.CD004816.pub4. 32. Fenwick, E, O'Brien, BJ, Briggs, A. Cost-effectiveness acceptability curves - facts, fallacies and frequently asked questions. Health Econ 2004;13:405-415. 33. Cantor S.B Medical.Cost - Effectiveness analysis, extended dominance, and ethics: a quantitative assessment. Med Decis Making. 1994; 14:259-65. 34. Hippisley-Cox J, Coupland C. Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database. BMJ. 2010 May 20; 340:c2197. doi: 10.1136/bmj.c2197 35. Hippisley-Cox J, Coupland C. Individualising the risks of statins in men and women in England and Wales: population-based cohort study.Heart. 2010 Jun;96(12):939-47. 36. Marks D, Wonderling D, Thorogood M et al. Cost-effectiveness analysis of different approaches of screening for familial hypercholesterolaemia. [See comment]. BMJ 2002; 324:1303-1306. 37. Marks D, Thorogood M, Neil HA, et al. Comparing costs and benefits over a 10 year period of strategies for familial hypercholesterolaemia screening. J Public Health Med 2003; 25:47-52. 38. Wonderling D, Umans-Eckenhausen MA, Marks D et al. Cost-effectiveness analysis of the genetic screening program for familial hypercholesterolemia in The Netherlands. Semin in Vasc Med 2004; 4:97-104. 39. National Institute for Health and Clinical Excellence. Cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. 2008. http://guidance.nice.org.uk/CG67.
URI:	http://wrap.warwick.ac.uk/id/eprint/37442

Data sourced from Thomson Reuters' Web of Knowledge

Request changes to a record

Actions (login required)

View Item